◼ Archived
Business
CBER official overruled review team’s rejection of new Replimune melanoma drug
An official within the FDA's CBER overruled a review team's initial rejection of a new Replimune melanoma drug.
Melanoma
11 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Melanoma
This hub groups 11 separate news trends connected to Melanoma, spanning June 22, 2026 through September 3, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 101 article observations and 90 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
◼ Archived
Business
🔮 fades ✓
Merck and Moderna say cancer vaccine shows promise in preventing recurrence of melanoma
Shares of Moderna have doubled after its cancer vaccine trial with Merck met key endpoints.
◼ Archived
Business
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna's stock surges as a melanoma vaccine developed with Merck shows promise in a large trial
◼ Archived
Business
🔮 fades ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial
◼ Archived
Health
🔮 fades ✓
Why cancer, not cost of living, may be the biggest issue in Iowa’s midterm elections
Iowa voters are prioritizing cancer over cost of living in the upcoming midterm elections.
◼ Archived
Business
🔮 fades ✓
FDA approves Replimune melanoma drug previously rejected twice
Replimune's melanoma drug wins FDA approval on third attempt, but stock price falls.
◼ Archived
Business
🔮 holds ✗
FDA Panel Votes In Favor of Replimune’s Melanoma Treatment
An FDA advisory committee has voted 10-3 in favor of Replimune’s oncolytic immunotherapy for melanoma, marking a turning point for the twice-rejected treatment.
◼ Archived
Health
🔮 fades ✓
How a Dermatologist Monitors Herself for Skin Cancer and the ‘Big Sign’ a Mole May Be Melanoma
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
Over 40? These Are the Sunscreens Dermatologists Actually Recommend
Dermatologists and experts are providing guidance on sunscreen selection and application to prevent skin cancer and manage aging skin.
◼ Archived
Health
🔮 fades ✓
Doctor Shares ABCDE Method To Tell Moles Apart From Skin Cancer
A doctor's simple method for distinguishing moles from skin cancer is trending worldwide.